MG
JAZZ icon

Marex Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

Marex Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,797
Closed -$237K – 1063
2025
Q3 		$237K Sell
1,797
-3,952
-69% -$474K ﹤0.01% 676
2025
Q2 		$610K Buy
5,749
+2,813
+96% +$306K 0.01% 353
2025
Q1 		$365K Buy
+2,936
New +$383K 0.01% 411
2024
Q4 		– Sell
-1,942
Closed -$216K – 761
2024
Q3 		$216K Sell
1,942
-877
-31% -$96.1K ﹤0.01% 460
2024
Q2 		$301K Buy
2,819
+1,064
+61% +$117K 0.01% 415
2024
Q1 		$211K Sell
1,755
-739
-30% -$90.5K 0.01% 382
2023
Q4 		$307K Buy
+2,494
New +$311K 0.01% 385

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Marex Group's JAZZ Position: Q4 2025 in Review

Marex Group sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2025, closing a stake of 1,797 shares — an estimated $237K sold.

Marex Group first reported a position in JAZZ in Q4 2023 and held it in 7 quarters. The position peaked at $610K in Q2 2025. 576 funds tracked by Wall St. Rank hold JAZZ as of Q4 2025.

  • Marex Group reported no remaining Jazz Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Marex Group sold 1,797 Jazz Pharmaceuticals shares in Q4 2025, an estimated $237K.
  • Marex Group first reported a position in Jazz Pharmaceuticals in Q4 2023 and held it in 7 quarters.
  • Marex Group's Jazz Pharmaceuticals position peaked at $610K in Q2 2025.
  • 576 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2025.

Based on Marex Group's 13F filing for Q4 2025, filed 12 Feb 2026.